Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also cause pregnancy complications and harm some users.

The evolution of controversial new weight loss drugs is shining a spotlight on a crippling, little-understood food phenomenon ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...